Allan May

President, CEO

From 1983-1997 Allan served Chief Business Officer or President of Technology and Medical companies including Fortune Systems (NASDAQ), Diasonics, Inc (NYSE) and OEC Medical Systems (NYSE), focusing on merger and acquisition transactions, and company turnaround operations.

Allan has been Co-Founder, CEO or Chairman of Nanostim, a start-up focused on developing a fully implantable cardiac rhythm device, Vascular Architects, a venture backed company focused on commercializing a lesser invasive surgical procedure, and bare metal and drug eluting stents for treating peripheral vascular disease, Athenagen (now CoMentus), focused on the development of novel therapeutics for pathological angiogenesis; MAST Immunosystems, commercializing an in vitro panel for allergy detection and identification; Intella Interventional Systems, a developer and marketer of novel catheters and balloon technology for cardiovascular disease; Quanam Medical, focused on drug eluting coronary stents; ImmuneTech, specializing in developing and marketing a testing concept for selected immunological disorders; NuGEN Technologies, focused on nucleic acid amplification; and several other MedTech or Biotech companies.

In 2005, Allan co-founded Life Science Angels (www.lifescienceangels.com), the largest angel organization in the U.S. focused solely on early stage medical device and life science start-ups, and comprised solely of high net worth individuals with extensive backgrounds in medical device or biotech operations. In 2007, Allan joined renowned inventor, entrepreneur and cardiologist, Dr. Thomas Fogarty, to establish a Emergent Medical Partners, a $70M venture capital fund solely focused on MedTech investing.

Allan is a member of the board of directors of the Kauffman Foundation's Angel Capital Education Foundation, a nonprofit devoted to the study of angel investing. He is also a member of the editorial board of MX Business Strategies for Medical Device executives, and speaks frequently on trends and developments affecting early stage biotech and life science investing.

David Danitz

Vice President, Research and Development

David Danitz has been working in the research and development arena for 13 years. He joined Novare Surgical in 2000. Mr. Danitz last served at Computer Motion as a project manager for the Zeus Surgical Robotic System. Prior to that, Mr. Danitz held a research engineering position at Exxon Production Research Center. Mr. Danitz earned a BSME degree with high honors from the University of California at Santa Barbara, and an SMME degree from the Massachusetts Institute of Technology.

Joe Guido

Vice President, Sales and Marketing

Mr. Guido has 16 years of medical device industry experience, holding a variety of positions in both Marketing and Sales. In May 2006, Mr. Guido joined Novare from Abbott Vascular where he served as Director of Strategic Marketing for the division's franchise business, Vessel Closure. Mr. Guido has also held senior level positions as Vice President of Marketing at Intuitive Surgical, Director of Marketing at Stryker Endoscopy as well as Sales roles with Davis & Geck. Mr. Guido received his M.B.A. from Pepperdine University and his B.S. from Villanova University.

Phoumren Tan

Vice President, Administration and Finance

Phoumren Tan joined Novare Surgical in 2002 as Controller and has held increasingly responsible roles in finance, strategic planning and information technology leading up to his current role of Vice President of Administration and Finance. Prior to joining Novare, Mr. Tan had over ten years experience in finance and accounting administration in both the medical device and information technology market segments. Mr. Tan joined Novare Surgical from JetStream Communications and Boston Scientific Corporation where he held senior accounting and supervisory positions. Mr. Tan has a BS degree in Business/Finance from San Jose State University.